Top News

Abraxis BioScience Spins off From APP Pharmaceuticals




Los Angeles-based Abraxis BioScience said this morning that it has spun-off from APP Pharmaceuticals, the firm said today. The firm will focus on drug development. The firm's major product, ABRAXANE, is used for treating cancer and other illnesses. According to Abraxis, it has been capitalized with $700M in cash and it will trade on the Nasdaq Global Market as ABII.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel